Crispr Therapeutics AG (NASDAQ:CRSP) saw a significant decrease in short interest in the month of November. As of November 29th, there was short interest totalling 3,620,000 shares, a decrease of 34.9% from the November 14th total of 5,560,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average trading volume of 914,900 shares, the short-interest ratio is presently 4.0 days.
CRSP has been the subject of a number of recent analyst reports. Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $69.54.
Shares of CRSP traded up $0.38 during trading hours on Thursday, reaching $66.03. 1,136,382 shares of the company traded hands, compared to its average volume of 712,154. The stock’s fifty day moving average is $57.87 and its 200 day moving average is $48.15. The stock has a market cap of $3.72 billion, a P/E ratio of -19.19 and a beta of 3.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. On average, equities research analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.
A number of large investors have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. raised its position in Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Crispr Therapeutics in the third quarter worth about $21,167,000. Price T Rowe Associates Inc. MD raised its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Wells Fargo & Company MN raised its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Crispr Therapeutics in the second quarter worth about $5,165,000. 49.82% of the stock is owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Quick Ratio
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.